. 2010 Jul 8;12(9):746–752. doi: 10.1111/j.1751-7176.2010.00335.x

Table III.

Insulin SI and GDR (Hyperinsulinemic Euglycemic Clamp)

Variable N_placebo/N_telmisartan	Observed Values, Mean (SD)				Adjusted Mean Change (SE) From Baseline^a
	Placebo		Telmisartan		Adjusted Mean Change (SE) From Baseline^a
	Baseline	Final	Baseline	Final	Placebo	Telmisartan	Δ^b	P Value
SI(Clamp), mg/kg min per μU/mL^c
Low‐dose insulin (60 mU/m²/min) (14/12)	0.0671 (0.0472)	0.0672 (0.0453)	0.0631 (0.0426)	0.0563 (0.0315)	0.0011 (0.00886)	−0.0073 (0.01014)	−0.0084	.5304
High‐dose insulin (120 mU/m²/min) (14/12)	0.0544 (0.0470)	0.0507 (0.0290)	0.0456 (0.0200)	0.0482 (0.0207)	−0.0010 (0.00646)	−0.0017 (0.00750)	−0.0007	.9467
GDR, mg/kg min^d
Low‐dose insulin (60 mU/m²/min) (14/13)	4.23 (2.04)	4.69 (1.98)	4.75 (2.73)	4.61 (1.89)	0.39 (0.351)	0.04 (0.376)	−0.35	.4977
High‐dose insulin (120 mU/m²/min) (14/13)	6.75 (3.48)	7.60 (2.31)	7.72 (3.16)	8.18 (2.09)	0.60 (0.425)	0.69 (0.453)	0.10	.8774

Abbreviations: GDR, glucose disposal rate; SD, standard deviation; SE, standard error of the mean; SI, sensitivity index. ^aModel including main effects of treatment and center with baseline as a covariate. ^bTelmisartan group minus placebo group. ^cResults from PP dataset. ^dResults from FAS.